文献速递慢性静脉疾病静脉血栓栓塞

对血栓后综合征患者合并腹股沟韧带以下延伸的慢性髂股静脉阻塞行血管内治疗

Endovascular treatment of chronic ilio-femoral vein obstruction with extension below the inguinal ligament in patients with post-thrombotic syndrome.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2024-01-17

本研究评估了慢性髂股静脉流出道阻塞合并血栓后综合征(PTS)患者跨越腹股沟韧带行血管内再通与支架置入的术后结局,连续纳入2018年1月至2022年2月的63例患者。结果显示技术成功率为100%,30天内无主要不良事件,2年一期通畅率为92.1%(95%CI 85.6%-99%),二期通畅率为98.4%(95%CI 95.4%-100%),VCSS与Villalta评分较基线显著改善。作者认为使用专用静脉支架跨越腹股沟韧带治疗有症状的髂股静脉疾病安全有效。

要点

  • 63例PTS合并慢性髂股静脉阻塞患者跨越腹股沟韧带行血管内再通与支架置入,技术成功率100%。
  • 30天内无主要不良事件,2年一期通畅率92.1%(95%CI 85.6%-99%),二期通畅率98.4%(95%CI 95.4%-100%)。
  • VCSS与Villalta评分中位改善分别为4分(IQR 2-7,P=.001)与3分(IQR 1.5-5,P=.001),VAS疼痛评分降低17 mm。

核心结论

  • 使用专用静脉支架跨越腹股沟韧带治疗有症状的髂股静脉疾病安全有效,2年一期与二期通畅率可接受。

研究设计与样本

  • 连续纳入2018年1月至2022年2月期间慢性髂股静脉流出道阻塞合并PTS并接受跨越腹股沟韧带血管内再通与支架置入的患者,共63例,平均年龄48.1±15.5岁,女性占61.9%。

主要发现

  • 术中及术后30天均未记录到并发症,技术成功率为100%。
  • 随访期间检出1例支架内闭塞和5例支架内再狭窄,未观察到支架断裂和/或移位。
  • 1年与2年一期通畅率分别为93.7%(95%CI 87.8%-99.9%)与92.1%(95%CI 85.6%-99%),2年二期通畅率为98.4%(95%CI 95.4%-100%),2例接受了靶血管血运重建。
  • 末次随访时VCSS与Villalta评分较基线中位改善分别为4分(IQR 2-7,P=.001)与3分(IQR 1.5-5,P=.001),2年随访时VAS疼痛评分降低17 mm。
  • 多变量分析显示,股静脉及股深静脉内小梁化(OR 1.89,95%CI 0.15-6.11,P=.043)与入院时Villalta评分>15分(OR 1.89,95%CI 0.15-6.11,P=.043)为随访期支架内闭塞的预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to evaluate postoperative outcomes of patients with chronic iliofemoral venous outflow obstruction and post-thrombotic syndrome (PTS) who underwent endovascular recanalization and stenting across the inguinal ligament. METHODS: All consecutive patients with chronic iliofemoral venous outflow obstruction and PTS were included in the analysis, from January 2018 and February 2022. Preoperative, intraoperative, and postoperative outcomes were assessed. Primary endpoints analyzed were major adverse events (MAEs) at 30 days and primary patency rate at 2 years of follow-up. Secondary endpoints assessed were secondary patency rate, target vessel revascularization, and clinical improvement evaluated with the Venous Clinical Severity Score (VCSS) classification, Villalta scale, and visual analog scale (VAS), respectively. RESULTS: A total of 63 patients (mean age, 48.1 ± 15.5 years; female, 61.9%) were evaluated. No intraoperative and 30-day postoperative complications were documented. The technical success rate was achieved at 100%. Overall, one in-stent occlusion and five in-stent restenosis were detected during follow-up. The primary patency rate was 93.7% (95% confidence interval [CI], 87.8%-99.9%) and 92.1% (95% CI, 85.6%-99%), at 1- and 2-year follow-up, respectively (Kaplan-Meier analysis). Target vessel revascularization was conducted in two cases, resulting in a secondary patency of 98.4% (95% CI, 95.4%-100%) at 2 years of follow-up. Stent fracture and/or migration were not observed during follow-up. A significant clinical improvement in the patient's quality of life was documented. The median improvement of VCSS and Villalta scores were 4 (interquartile range, 2-7; P = .001), and 3 (interquartile range, 1.5-5; P = .001) vs baseline at the last follow-up. Overall, pain reduction of 17 mm on the VAS scale was documented at 2 years of follow-up. At multivariate analysis, presence of trabeculation into the femoral vein and deep femoral vein (odds ratio, 1.89; 95% CI, 0.15-6.11; P = .043), and Villalta scale >15 points at admission (odds ratio, 1.89; 95% CI, 0.15-6.11; P = .043) were predictive for in-stent occlusion during the follow-up. CONCLUSIONS: The use of a dedicated venous stent across the inguinal ligament was safe and effective for the treatment of symptomatic iliofemoral venous disease with acceptable primary and secondary patency rates at 2 years of follow-up.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Ardita V, Galati N, Miglioranza E, et al. Endovascular treatment of chronic ilio-femoral vein obstruction with extension below the inguinal ligament in patients with post-thrombotic syndrome. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38237677. doi:10.1016/j.jvsv.2024.101816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。